Enhancing the HemOnc Knowledgebase of Chemotherapy Drugs and Regimens

项目摘要 系统性癌症治疗改变了许多癌症患者的面貌，但 是有毒的，通常以复杂的组合和方案给药。2011年，我们开始建设 作为血液学和肿瘤学医疗保健免费开放资源的hemOnc.org网站 专业人士。HemOnc.org包含关于抗癌药物、疗法和 指导方针，现在是同类资源中最大的。2020年，有250,000个独一无二的 来自181个国家的访问者和100万的页面浏览量。用户主要分布在临床医生之间 和药剂师，供受训人员和有经验的从业者使用。翻译 研究人员还利用该网站作为领域知识的来源。从2017年开始，我们 规范了hemOnc.org上大部分内容的结构，使其能够转换为 一种结构化的词汇，hemOnc。截至2021年1月，hemOnc包含83,879个概念 涉及30个概念类，以及涉及45种关系类型的223,039个关系。显式 在hemOnc和RxNorm、CanMED、SNOMED-CT、OncoTree和NCI之间存在映射 同义词词典。几个组织和项目积极使用或正在评估hemOnc， 包括AACR项目精灵，ITCR资助的DeepPhe项目，对 癌症联盟和生物门户网站。除了保持内容的稳定增长外， 在过去的九年里，我们的目标是加强hemOnc.org的网站和 通过以下五个具体目标实现hemOnc本体：1)提出交互式分级方案 网站上的图表；2)允许动态时间探索养生法、研究和 作者使用交互式方案浏览器；3)增长和提炼hemOnc本体；4)构建 最重要的抗癌方案的结构化摘要和叙述性概要， 包括确定在代表性不足的人群中专门评估的方案；5) 培育强大的用户社区。这项工作将由一支经验丰富的 临床医生和翻译研究人员。

Project Summary Systemic cancer treatments have transformed the landscape for many patients with cancer, yet are toxic and often given in complicated combinations and protocols. In 2011, we began to build the HemOnc.org website as a free and open resource for hematology and oncology healthcare professionals. HemOnc.org contains granular information on anti-cancer drugs, regimens, and guidelines, and is now the largest resource of its kind. In 2020, there were >250,000 unique visitors and >1,000,000 pageviews from 181 countries. Users are primarily split between clinicians and pharmacists, with utilization by trainees as well as experienced practitioners. Translational researchers also utilize the site as a source of domain knowledge. Beginning in 2017, we formalized the structure of much of the content on HemOnc.org, enabling its transformation into a structured vocabulary, HemOnc. As of January 2021, HemOnc comprises 83,879 concepts across 30 concept classes, and 223,039 relationships across 45 relationship types. Explicit mappings exist between HemOnc and RxNorm, CanMED, SNOMED-CT, OncoTree, and the NCI Thesaurus. Several organizations and projects actively utilize or are evaluating HemOnc, including AACR Project GENIE, the ITCR-funded DeepPhe project, the Variant Interpretation for Cancer Consortium, and cBioPortal. In addition to maintaining the steady growth in content that has taken place over the past nine years, we aim to enhance the HemOnc.org website and HemOnc ontology through the following five specific aims: 1) present interactive ranked regimen graphs on the website; 2) allow for dynamic temporal exploration of regimens, studies, and authors with an interactive Regimen Browser; 3) grow and refine the HemOnc ontology; 4) build structured summaries and narrative synopses for the most important anticancer regimens, including identification of regimens specifically evaluated in underrepresented populations; 5) cultivate a robust user community. This work will be undertaken by an accomplished team of clinicians and translational researchers.